Clinical Scorecard: Surgical Outcomes of Retroperitoneal Lymph Node Dissection for Growing Teratoma Syndrome in Testicular Cancer: A Comprehensive Systematic Review

At a Glance

Key Highlights

• GTS incidence ranges from 2.8% to 7.6% among NSGCT patients treated with chemotherapy, predominantly affecting young males aged 16–38 years.
• GTS is unresponsive to chemotherapy and radiotherapy; surgical resection via RPLND is the standard treatment.
• Postoperative complication rates vary from 12.5% to 44%, with serious complications (Clavien-Dindo ≥ III) in up to 25%; disease-free survival ranges from 41.7% to 100%.

Guideline-Based Recommendations

Diagnosis

• Identify GTS by growth of masses during or after chemotherapy despite normalization of serum tumour markers.
• Confirm diagnosis histologically by presence of mature teratoma tissue in surgical specimens.

Management

• Surgical removal of retroperitoneal teratoma masses via retroperitoneal lymph node dissection (RPLND) is the standard of care.
• Chemotherapy is ineffective against GTS and should not be relied upon for treatment.
• Early recognition and timely surgery are critical to prevent morbidity from tumour bulk or compression.

Monitoring & Follow-up

• Monitor patients post-chemotherapy for enlarging masses and symptoms such as compressive effects.
• Follow-up duration in studies ranged from 8 to 103 months to assess disease-free and overall survival.

Risks

• Risk of somatic-type malignant transformation within mature teratoma tissue (7.7–8.3%).
• Potential for significant surgical morbidity including blood loss and postoperative complications.
• Delayed diagnosis may lead to increased tumour bulk and compression of adjacent structures.

Patient & Prescribing Data

Patients with NSGCTs who develop GTS after chemotherapy, median age 16–38 years.

Most patients received BEP chemotherapy prior to RPLND; chemotherapy interruption was rare (4.5%) and usually due to compressive symptoms.

Clinical Best Practices

• Use multidisciplinary approach including oncologists and experienced surgical teams for management of GTS.
• Perform thorough pathological evaluation of RPLND specimens to confirm mature teratoma and exclude malignant transformation.
• Plan surgery considering potential need for adjunctive procedures due to tumour bulk or involvement of adjacent structures.
• Implement close postoperative monitoring for complications and long-term follow-up to assess oncological outcomes.

References

• Logothetis et al., 1982 - Original description of Growing Teratoma Syndrome
• PRISMA 2020 guidelines
• ROBINS-I tool for risk of bias assessment